Maya Jay

building something new to empower patients @FlagshipPioneer 🚀 | prev BioxML 🧬@LilaSciences @PiN_Harvard @MIT | she/her/dr, views are my own

[Maya Jay @neurojaym]

A little late to the Twitter party, but happy to share my first (co-)first author publication is finally out in @Nature! A dream collab with @vulcnethologist @GillisDub exploring the role of #dopamine in real-time action selection in naive mice. More below from @Datta_Lab👇🏽💥

[Maya Jay @neurojaym]

@artemg314 @PheironAI

[Maya Jay @neurojaym]

@owl_posting @FoundationOAI amazing news!! congrats!

[Maya Jay @neurojaym]

deleted this app six months ago and became suspiciously well-adjusted. spent the time building something cool. but i missed strangers' opinions too much.

hello timeline goblins, i'm back to ruin all that progress with you

(will explain the thing eventually, goblin's honor)

[Maya Jay @neurojaym]

@KR_Skelly @tacitlabsco Congrats @KR_Skelly !!

[Maya Jay @neurojaym]

@zavaindar @_DimensionCap @SimonDBarnett @bauer_lesavage the design work is elite!

[Maya Jay @neurojaym]

@patricksmalone nominating @RuxandraTeslo

[Maya Jay @neurojaym]

@owl_posting I wonder if in this model the training of a pharmacist needs to morph closer to that of a doctor in order to maintain guardrails while still enabling self-experimentation/treatment.

or you enable some interesting algorithmic personalized pricing to disincentivize reckless use

[Maya Jay @neurojaym]

@cgeorgiaw @AAlphaBio Curious what you think about the merits of yeast assays (like Y2H) vs AP-MS assays and their value and fidelity for measuring PPIs at scale. Useful data, but is it the best way to measure?

[Maya Jay @neurojaym]

@parmita 🤚 me!!

[Maya Jay @neurojaym]

@dwarkesh_sp Nominating @blsabatini, Karel Svoboda, @gershbrain or @Nancy_Kanwisher. Also Liam Paninski

[Maya Jay @neurojaym]

@BenKompa @LilaSciences 2025 we're locked in

[Maya Jay @neurojaym]

@owl_posting Loved reading this - in your infinite free time, you should write more non-science long form posts!!

[Maya Jay @neurojaym]

@parmita Every paper that claims that some multi-layer gizmo like this is going to magically give rise to some "emergent virtual cell" causes my eyes to roll so far back into my head that i can see my amygdala on fire

[Andrew Beam @AndrewLBeam]

Awesome list @chrisbarber! @LilaSciences is hiring across a ton of areas including RL, infra, ML Ops, ML for bio and materials. If you’re at NeurIPS please reach out or come join us at our happy hour!

RSVP: https://t.co/xuRcQwuhfG

A big chunk of the team will be there and will be a great opportunity to learn more about Lila

[Maya Jay @neurojaym]

@iskander they're asking US to fix it?

[U.S. Department of Energy @ENERGY]

President Trump is launching the most powerful scientific platform to ever be built, reminiscent of the Manhattan Project and Apollo programs: Genesis Mission.

[Maya Jay @neurojaym]

@iskander If you can get access, Causaly is highly specialized for biomedical literature and drug targets. Seconding @elicitorg and maybe @perplexity_ai for completeness.

[Maya Jay @neurojaym]

@zavaindar @incredutility Even if 0 shot binder design approaches solved, how much of a bottleneck is screening for X-reactivity/specificity?

Not to mention all the other developability/PK-in-human challenges, which are more well accepted open grand challenges

[Kenny Workman @kenbwork]

Transcriptomics is very useful but overdiscussed because measurement tools are becoming mature. No one is actually ready for the complexity of proteomics. Can be thousands of proteoforms for a single protein, all with identical mass, near identical fragmentation patterns, very low abundance. Crazy numbers here: 10^6-10^8 *types* per cell and ~10^10 total counts. Most current tools (eg. many MS flavors) work with bulk samples and even then cannot pick out subtle chemical differences, blending distinct molecules and obfuscating potentially important biochemistry.